Sarasin & Partners’s Gilead Sciences GILD Stock Holding History

Sarasin & Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-14,500	Closed	-$1.47M	–	133
2015 Q4	$1.47M	Buy	14,500 +4,000	+38%	+$416K	0.02%	102
2015 Q3	$1.03M	Sell	10,500 -10,500	-50%	-$1.17M	0.02%	107
2015 Q2	$2.46M	Sell	21,000 -12,200	-37%	-$1.33M	0.04%	94
2015 Q1	$3.26M	Sell	33,200 -40,400	-55%	-$4.1M	0.05%	91
2014 Q4	$6.94M	Hold	73,600	–	–	0.1%	68
2014 Q3	$7.83M	Hold	73,600	–	–	0.11%	66
2014 Q2	$6.1M	Sell	73,600 -43,500	-37%	-$3.39M	0.09%	73
2014 Q1	$8.3M	Buy	117,100 +27,900	+31%	+$2.19M	0.12%	64
2013 Q4	$6.7M	Hold	89,200	–	–	0.09%	79
2013 Q3	$5.61M	Sell	89,200 -54,400	-38%	-$3.25M	0.09%	77
2013 Q2	$7.36M	Buy	+143,600	New	+$7.48M	0.1%	68

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sarasin & Partners's GILD Position: Q1 2016 in Review

Sarasin & Partners sold out of Gilead Sciences (GILD) in Q1 2016, closing a stake of 14,500 shares — an estimated $1.47M sold.

Sarasin & Partners first reported a position in GILD in Q2 2013 and held it in 11 quarters. The position peaked at $8.3M in Q1 2014. 1,629 funds tracked by Wall St. Rank hold GILD as of Q1 2016.

Sarasin & Partners reported no remaining Gilead Sciences position as of Q1 2016 after selling out during the quarter.
Sarasin & Partners sold 14,500 Gilead Sciences shares in Q1 2016, an estimated $1.47M.
Sarasin & Partners first reported a position in Gilead Sciences in Q2 2013 and held it in 11 quarters.
Sarasin & Partners's Gilead Sciences position peaked at $8.3M in Q1 2014.
1,629 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2016.

Based on Sarasin & Partners's 13F filing for Q1 2016, filed 27 Apr 2016.